Search Tag: semaglutide
2025 13 May
A new head-to-head clinical trial comparing tirzepatide and semaglutide for weight loss in people with obesity but without diabetes demonstrates that tirzepatide led to significantly greater weight reduction. Over a 72-week period, participants receiving tirzepatide achieved an average weight loss of 20.2%, compared to 13.7% with semaglutide—a difference...Read more
2025 07 May
New research published in the New England Journal of Medicine reveals that semaglutide effectively treats liver disease in nearly two-thirds of patients, offering new hope for those with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. MASH is a progressive form of Metabolic dysfunction-associated steatotic...Read more
2025 09 Apr
As the popularity of weight loss drugs like Mounjaro, Ozempic, and Wegovy continues to rise, many users report eating less processed food and drinking less soda — a trend that’s already prompting food and beverage companies to rethink their marketing strategies. Originally developed for blood sugar control in diabetes, these drugs mimic a naturally...Read more
2025 18 Feb
According to new research, semaglutide (sold as Ozempic for diabetes and Wegovy for obesity) may also help curb alcohol intake. The study is published in JAMA Psychiatry . Findings show that weekly injections of semaglutide significantly reduced alcohol cravings, drinking quantity, and the frequency of heavy drinking days in adults with symptoms...Read more
2025 28 Jan
A recent study by the Boston University School of Public Health (BUSPH) highlights significant barriers faced by individuals with obesity in accessing weight-loss medications like semaglutide, particularly within a healthcare system that has historically deprioritised obesity treatment. Initially developed to manage diabetes, glucagon-like...Read more
2024 29 Oct
According to a study led by the Yale School of Public Health and the University of Florida, expanding access to new, highly effective weight-loss medications could save over 40,000 lives annually in the U.S. The research highlights the urgency of removing barriers that prevent people from accessing effective obesity treatments, a crucial step toward...Read more
2024 17 Sep
A new study has identified key factors that influence long-term weight loss in patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or obesity. The findings are published in JAMA Network Open. In patients with obesity treated with semaglutide or liraglutide, study researchers observed...Read more
2024 26 Aug
According to a new study, the anti-obesity drug semaglutide may help prevent heart attacks and other major cardiac events in overweight individuals with cardiovascular disease, whether or not they also have heart failure. The study is published in The Lancet. This research builds on previous findings, which showed that weekly injections of semaglutide...Read more
2024 24 Jun
Semaglutide has demonstrated significant symptom improvement in both men and women suffering from a common type of heart failure with limited treatment options. Research presented at the American Diabetes Association’s 2024 Scientific Sessions and published in the Journal of the American College of Cardiology reveals that women achieved greater...Read more
2024 21 Jun
The World Health Organization (WHO) has issued a global alert about fake versions of Ozempic, a drug that has gained significant popularity for weight loss. Although Ozempic is primarily prescribed for type 2 diabetes, it is sometimes referred to as a "skinny jab" due to its weight-loss effects. The WHO has warned that the fake versions of Ozempic...Read more
2024 30 May
Recent research presented at Heart Failure 2024 highlights that semaglutide reduces the necessity for loop diuretics and their dosage while also positively impacting symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF), irrespective of their diuretic regimen. HFpEF occurs when the...Read more
2024 22 May
A recent analysis shows that semaglutide, a prescription drug (brand names Wegovy and Ozempic), may reduce the risk of heart attacks and strokes in individuals, regardless of their weight loss success. Prof John Deanfield from the UCL Institute of Cardiovascular Disease led the study. Researchers analysed data from the Semaglutide and...Read more
2024 17 Apr
Obesity is a global pandemic, with prevalence in the U.S. reaching 42.4% in 2018 and projected to rise to around 50% by 2030. It is linked to chronic medical conditions that increase morbidity and mortality, imposing a substantial burden on annual healthcare spending. Given the high prevalence and adverse impact of obesity on health and healthcare...Read more
2023 25 Aug
In recent breakthrough research presented during a Hot Line session at ESC Congress 2023, semaglutide's effectiveness in improving symptoms and physical function related to heart failure and inducing greater weight loss was reported. Nearly 50% of heart failure patients are affected by heart failure with preserved ejection fraction (HFpEF)....Read more
2023 04 Jul
A recent study conducted by researchers at University College Cork (UCC) and the University of Galway suggests that changing how we discuss obesity is necessary to enhance public understanding of the disease. The researchers propose that the term "obesity" should be renamed to facilitate better comprehension among the public and policymakers, ultimately...Read more
2023 19 Apr
A new study suggests that some anti-obesity medications can be produced and sold at much lower prices than their current high costs, making them more accessible worldwide. The study is published in Obesity. Study authors highlight the need for a public health approach that prioritises improving access to medications instead of allowing...Read more